S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
NYSE:RMD

ResMed (RMD) Stock Price, News & Analysis

$178.85
+1.24 (+0.70%)
(As of 04/19/2024 ET)
Today's Range
$176.92
$179.43
50-Day Range
$173.72
$198.04
52-Week Range
$132.24
$243.52
Volume
1.30 million shs
Average Volume
1.03 million shs
Market Capitalization
$26.31 billion
P/E Ratio
29.56
Dividend Yield
1.07%
Price Target
$199.20

ResMed MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
11.4% Upside
$199.20 Price Target
Short Interest
Bearish
5.36% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.64mentions of ResMed in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$2.05 M Sold Last Quarter
Proj. Earnings Growth
10.84%
From $7.47 to $8.28 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.82 out of 5 stars

Medical Sector

38th out of 908 stocks

Surgical & Medical Instruments Industry

4th out of 93 stocks

RMD stock logo

About ResMed Stock (NYSE:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Stock Price History

RMD Stock News Headlines

Reviewing ResMed (NYSE:RMD) and Orthofix Medical (NASDAQ:OFIX)
ResMed (RMD) Set to Announce Earnings on Thursday
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
ResMed Unusual Options Activity For April 17
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
ResMed: Not A Sleeper
ResMed Inc Director Peter Farrell Sells 23,535 Shares
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/24/2024
Ex-Dividend for 3/14 Dividend
2/07/2024
Dividend Payable
3/14/2024
Today
4/20/2024
Next Earnings (Confirmed)
4/25/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
76115210
Employees
10,140
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$199.20
High Stock Price Target
$230.00
Low Stock Price Target
$165.00
Potential Upside/Downside
+11.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$897.56 million
Pretax Margin
24.37%

Debt

Sales & Book Value

Annual Sales
$4.22 billion
Cash Flow
$7.86 per share
Book Value
$28.11 per share

Miscellaneous

Free Float
145,309,000
Market Cap
$26.31 billion
Optionable
Optionable
Beta
0.67

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Should I Buy ResMed Stock? RMD Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • ResMed Inc. has been consistently introducing innovative medical devices and cloud-based software applications, staying ahead in the healthcare technology sector.
  • The company's focus on respiratory care and software as a service segments aligns with the growing demand for remote patient monitoring and digital health solutions.
  • ResMed's recent stock price performance has shown positive momentum, indicating investor confidence and potential for capital appreciation.
  • ResMed's diverse product portfolio catering to various respiratory disorders provides a competitive edge in the market and potential for revenue growth.
  • The company's strategic partnerships and acquisitions enhance its market presence and offer opportunities for expansion into new healthcare segments.

Cons

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • ResMed Inc. operates in a highly competitive industry with evolving regulations and technological advancements, leading to potential challenges in maintaining market share.
  • The company's reliance on continuous innovation and product development may pose risks of regulatory hurdles, delays, or product recalls affecting financial performance.
  • Fluctuations in healthcare policies and reimbursement rates could impact ResMed's revenue streams and profitability, adding uncertainty to investment returns.
  • Global economic conditions and geopolitical factors may influence ResMed's international operations and expose the company to currency exchange risks.
  • Investors should consider the cyclicality of the healthcare sector, which could affect ResMed's financial results and stock performance during economic downturns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

RMD Stock Analysis - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price target for 2024?

10 analysts have issued 1-year price targets for ResMed's shares. Their RMD share price targets range from $165.00 to $230.00. On average, they anticipate the company's share price to reach $199.20 in the next twelve months. This suggests a possible upside of 11.4% from the stock's current price.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2024?

ResMed's stock was trading at $172.02 at the beginning of 2024. Since then, RMD stock has increased by 4.0% and is now trading at $178.85.
View the best growth stocks for 2024 here
.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our RMD earnings forecast
.

How can I listen to ResMed's earnings call?

ResMed will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13745785".

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings data on Wednesday, January, 24th. The medical equipment provider reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.81 by $0.07. The medical equipment provider earned $1.16 billion during the quarter, compared to analysts' expectations of $1.15 billion. ResMed had a trailing twelve-month return on equity of 23.86% and a net margin of 19.77%. ResMed's revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.66 EPS.
Read the conference call transcript
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Wednesday, January 24th. Stockholders of record on Thursday, February 8th will be paid a dividend of $0.48 per share on Thursday, March 14th. This represents a $1.92 annualized dividend and a yield of 1.07%. The ex-dividend date of this dividend is Wednesday, February 7th.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.92 per share and currently has a dividend yield of 1.08%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 31.74%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 23.19% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (0.40%), Los Angeles Capital Management LLC (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), Confluence Investment Management LLC (0.09%), ST Germain D J Co. Inc. (0.07%) and Synergy Asset Management LLC (0.05%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Michael J Rider, Peter C Farrell, Rajwant Sodhi and Robert Andrew Douglas.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
This page (NYSE:RMD) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners